gedifferentieerd schildkliercarcinoom differentiated thyroid cancer ablation therapy ablatie therapie recombinant TSH thyroid hormone withdrawal schildklierhormoon onttrekking I-131 therapie
Conditions
Interventions
Study procedures:
After total thyroidectomy and histological confirmation of differentiated thyroid cancer substitution therapy is started (levothyroxine) to reach a TSH level < 0.3 mU/l.
3-6 WEEKS
Sponsors
Prof.dr. T.P. Links, endocrinologist
Eligibility
Inclusion criteria
Inclusion criteria: 1. Low and high risk patients (according American Joint Committee on Cancer, AJCC 6) with recently diagnosed histological proven DTC, who have to be treated with ablation therapy. TNM stages T1>1cm, T2, T3, N0, N1, M0 are to be included; 2. Aged 18 years or older; 3. Not pregnant; 4. No major concurrent diseases (such as instable cardiovascular disease, concurrent malignancy treated 40ml/min); 6. No iodine containing medication or recent history of iodine containing imaging contrast agents; 7. Male and female.
Exclusion criteria
Exclusion criteria: 1. Stage T4; 2. Stage M1 when known before ablation; 3. Stage M1 known after ablation (remove from sequential analysis); 4. Tg antibodies positive at diagnosis; 5. Undetectable Tg during rhTSH stimulation at the time of ablation therapy (remove from sequential analysis).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful ablation defined as: rhTSH Tg<1ng/ml, negative rhTSH dx WBS, negative US and negative Tg antibodies. | — |
Contacts
Public ContactT.P. Links
Hanzeplein 1
Outcome results
None listed